(Q38018653)

27 August 2017

title

The right compound in the right assay at the right time: an integrated discovery DMPK strategy (English)

1 reference

27 August 2017

Peter Ballard

1

1 reference

27 August 2017

Patrick Brassil

2

1 reference

27 August 2017

Khanh H Bui

3

1 reference

27 August 2017

Hugues Dolgos

4

1 reference

27 August 2017

Carl Petersson

5

1 reference

27 August 2017

Anders Tunek

6

1 reference

27 August 2017

Peter J H Webborn

7

1 reference

27 August 2017

language of work or name

English

0 references

publication date

15 June 2012

1 reference

27 August 2017

published in

Drug Metabolism Reviews

1 reference

27 August 2017

volume

44

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

224-252

1 reference

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Predicting circulating human metabolites: how good are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights, and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Trial watch: Phase II failures: 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Caco-2 monolayers in experimental and theoretical predictions of drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Monoamine oxidase inactivation: from pathophysiology to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Pharmacokinetics of methylergometrine in the rat: evidence for enterohepatic recirculation by a linked-rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Role of the red blood cell in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Profiling drug-like properties in discovery research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Strategies to assess blood-brain barrier penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Classification analysis of P-glycoprotein substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

A new multidrug resistance protein at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Drug interactions at the blood-brain barrier: fact or fantasy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Development of a high-throughput brain slice method for studying drug distribution in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Improved measurement of drug exposure in the brain using drug-specific correction for residual blood

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Optimising in vivo pharmacology studies--Practical PKPD considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

In vitro-in vivo correlation of hepatobiliary drug clearance in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Regulation of hepatic ABCC transporters by xenobiotics and in disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Principles of covalent binding of reactive metabolites and examples of activation of bis-electrophiles by conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Structure-brain exposure relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Role of phase II drug metabolizing enzymes in cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Using the Golden Triangle to optimize clearance and oral absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Guidance in the setting of drug particle size specifications to minimize variability in absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Pharmaceutical profiling in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

UDP-glucuronosyltransferases and clinical drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Strategy for genotoxicity testing--metabolic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Human clearance prediction: shifting the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

In silico prediction of biliary excretion of drugs in rats based on physicochemical properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Contrasting influence of NADPH and a NADPH-regenerating system on the metabolism of carbonyl-containing compounds in hepatic microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Lumping of whole-body physiologically based pharmacokinetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Effect of Altered Plasma Protein Binding on Apparent Volume of Distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Prodrugs: design and clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Assessing brain free fraction in early drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Time-dependent CYP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Mechanistic approaches to volume of distribution predictions: understanding the processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Transporters as a determinant of drug clearance and tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Structure-based drug metabolism predictions for drug design.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Controversies in allometric scaling for predicting human drug clearance: an historical problem and reflections on what works and what does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Drug metabolism for the perplexed medicinal chemist

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Measurement of the renal clearance of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Membrane transport of drugs in different regions of the intestinal tract of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Lipophilicity in PK design: methyl, ethyl, futile

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Importance of drug transporters in pharmacokinetics and drug safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Lipophilicity in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

A comparison of physiochemical property profiles of development and marketed oral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

In silico approaches for predicting ADME properties of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2012.691099

10.3109/03602532.2012.691099

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference